Madrigal Pharmaceuticals (MDGL) Non-Current Deffered Revenue (2010)
Madrigal Pharmaceuticals (MDGL) posted quarterly Non-Current Deffered Revenue of $2.2 million for Q4 2010.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Non-Current Deffered Revenue (2010) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Non-Current Deffered Revenue for 1 consecutive years, with $2.2 million the latest figure, recorded in Q4 2010.
- In Q4 2010, Non-Current Deffered Revenue changed N/A year-over-year to $2.2 million; the TTM figure through Dec 2010 stood at $2.2 million (changed N/A YoY), while the FY2010 annual figure was $2.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $2.2 million in Q4 2010 per MDGL's latest filing.
- Across five years, Non-Current Deffered Revenue topped out at $2.2 million in Q4 2010 and bottomed at $2.2 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 14.93 Bn | - | - |